Medpace Holdings reported its third quarter 2026 results, highlighting a major update to its capital allocation strategy. While the primary financial results were furnished via a separate exhibit and not detailed in the summary 8-K filing, the company announced a significant expansion of its share buyback capacity.
Key Highlights
- Authorized a new $1.0 billion share repurchase program effective October 20, 2026, through December 31, 2028.
- Terminated the previous repurchase authorization, which had $527.0 million in capacity remaining at the time of cancellation.
- Intends to fund future share repurchases using existing cash on hand via open market or private transactions.